Known targets — ChEMBL curated mechanism
ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO
The experimentally established mechanism targets of Melagatran. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 20/20 | 0.63 |
| ▸ | F10 | P00742 | 1/20 | 0.56 |
| ▸ | PROC | P04070 | 1/20 | 0.56 |
| ▸ | F7 | P08709 | 1/20 | 0.56 |
| ▸ | MASP2 | O00187 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Melagatran SCHEMBL27557537 | 1.00 | F2 (0.63) | F2F10PROCF7MASP2 | |
| Melagatran SCHEMBL20567754 | 0.99 | F2 (0.64) | F2F10PROCF7MASP2 | |
| Melagatran SCHEMBL8083301 | 0.99 | F2 (0.64) | F2F10PROCF7MASP2 | |
| Melagatran SCHEMBL23840802 | 0.99 | F2 (0.64) | F2F10PROCF7MASP2 | |
| Melagatran SCHEMBL27652 | 0.99 | F2 (0.64) | F2F10PROCF7MASP2 | |
| Melagatran SCHEMBL3209070 | 0.98 | F2 (0.63) | F2F10PROCF7MASP2 | |
| Melagatran SCHEMBL29160734 | 0.98 | F2 (0.63) | F2F10PROCF7MASP2 | |
| SCHEMBL23793366 | 0.98 | F2 (0.62) | F2F10PROCF7MASP2 | |
| SCHEMBL23840772 | 0.95 | F2 (0.64) | F2F10PROCF7 | |
| SCHEMBL23840808 | 0.95 | F2 (0.64) | F2F10PROCF7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100537598-C | Substantially crystalline form of melagatran | ASTRAZENECA AB (SE) | 2009-09-09 | — | — | CN | disclosed |
| EP-1196431-B1 | A SUBSTANTIALLY CRYSTALLINE FORM OF MELAGATRAN | ASTRAZENECA AB (SE) | 2006-09-13 | — | — | EP | disclosed |
| US-20060178312-A1 | Process for the production of melagatran | ASTRAZENECA AB (SE) | 2006-08-10 | — | — | US | disclosed |
| CN-1809585-A | Process for the production of melagatran | ASTRAZENECA AB (SE) | 2006-07-26 | — | — | CN | disclosed |
| EP-1641814-A1 | NEW PROCESS FOR THE PRODUCTION OF MELAGATRAN | AstraZeneca AB (SE) | 2006-04-05 | — | — | EP | disclosed |
| WO-2004113364-A1 | NEW PROCESS FOR THE PRODUCTION OF MELAGATRAN | ASTRAZENECA AB (SE) | 2004-12-29 | — | — | WO | disclosed |
| US-6479078-B1 | Substantially crystalline form of melagatran | ASTRAZENECA AB (SE) | 2002-11-12 | — | — | US | disclosed |
| CN-1359389-A | Substantially crystalline form of melagatran | ASTRAZENECA AB (SE) | 2002-07-17 | — | — | CN | disclosed |
| EP-1196431-A1 | A SUBSTANTIALLY CRYSTALLINE FORM OF MELAGATRAN | AstraZeneca AB (SE) | 2002-04-17 | — | — | EP | disclosed |
| WO-2001002426-A1 | A SUBSTANTIALLY CRYSTALLINE FORM OF MELAGATRAN | ASTRAZENECA AB (SE) | 2001-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060178312-A1 | Process for the production of melagatran | ME1, MGAM, BLVRB | F2 1265/4885F10 1401/4885PROC 487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.